GlaxoSmithKline said yesterday its combination asthma drug Seretide had become the first drug to reduce the risk of death in patients with chronic obstructive pulmonary disease (COPD). GlaxoSmithKline ...
Seretide/Advair is GSK’s best-selling drug, and the line was extended in 2003 when the European Union approved the higher-dose 500 Accuhaler for the symptomatic treatment of severe COPD, i.e., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results